University of Chicago chosen as a center for new cancer clinical trials network

May 12, 2014

A team from the University of Chicago Medicine Comprehensive Cancer Center has received a five-year, $3.9-million award from the National Cancer Institute to serve as a Lead Academic Participating Site for the newly created National Clinical Trials Network (NCTN). The University of Chicago team received the best possible score in the highly competitive application process.

The new network is designed to improve the speed and efficiency of cancer clinical trials, according to the National Cancer Institute. The NCTN -- which will focus on early and late stage clinical trials for adults with cancer -- will consist of fewer but larger groups of investigators and will distribute resources in a more effective way.

Lead Academic Participating Site grants, created specifically for the NCTN, will provide scientific leadership in development and conduct of clinical trials in association with the adult clinical trial groups. They will perform preliminary studies to prepare for large-scale testing, conduct related studies to support specific trials, provide mentoring for junior faculty, and help recruit appropriate patients to Network trials, especially those expected to have a significant positive impact on cancer treatment.

The University of Chicago is one of up to 30 lead sites in the United States and the only one in Illinois.

"Our cancer center has a well-deserved reputation for high-impact clinical research and a deep and long-standing commitment to the former cancer cooperative groups that now comprise the NCTN," said Hedy Kindler, MD, associate professor of medicine at the University of Chicago and lead principal investigator for the Chicago site. "This grant will enable us to provide outstanding multidisciplinary scientific and administrative leadership in the design and implementation of innovative and potentially practice-changing clinical trials within the NCTN."

NCTN trials will set the standard for cancer treatment in the US and across the world, Kindler said. The significant recent advances in the basic sciences cannot benefit patients unless new treatments are proven safe and beneficial in the clinical setting.

The NCTN was created to consolidate the National Cancer Institute's clinical trials program. It replaces a 55-year-old system, the NCI National Clinical Trials Cooperative Group Program, with a new, more efficient structure. The network combines many smaller highly specialized groups -- focused on areas such as pediatric, breast, bowel or gynecological cancers -- into a few large cooperative groups in order to enhance system integration and cooperation.

The NCTN represents "an unmatched effort to integrate and streamline the process of cancer clinical trials research," said James Doroshow, MD, deputy director for clinical and translational research at NCI in a statement released by NCI last month.

The remodeling follows a 2010 report from the Institute of Medicine that recommended significant changes to hasten the initiation and completion of cancer clinical trials. The report stressed four goals: The new network is also taking steps to standardize the prioritization of new studies and to put in place a unified system -- including a central institutional review board that will cover studies conducted by the entire system -- to protect research subjects at more than 3,000 clinical trial sites.

"As a national leader in designing, conducting and analyzing all phases of clinical trials, the University of Chicago is well positioned to play a leadership role in the new network," said Michelle Le Beau, PhD, Arthur and Marian Edelstein Professor of Medicine and Director of the University of Chicago Medicine Comprehensive Cancer Center. "Selection as an NCTN Lead Academic Participating Site reflects our commitment, historic leadership and deep experience in conducting clinical trials to evaluate the newest strategies for cancer prevention, diagnosis and treatment."

In another major role, University of Chicago statistician James Dignam, PhD, associate professor of biostatistics, has been named as a principal investigator for the Statistics and Data Management Center of one of the new NCTN groups. Dignam and colleagues will provide statistical and data management support for the newly created NRG Oncology Group. NRG brings together three former clinical trial groups from the NCI Cooperative Group program: the National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group and the Gynecologic Oncology Group.
-end-
Clinical trials are central to the development of novel and life-saving cancer detection, prevention or treatment strategies. The conduct of NCI-supported trials involves a complex system of designing, reviewing and initiating studies.

Lead Academic Participating Sites are funded by the National Cancer Institute, grant number U10CA180854.

University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.